Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05114460 · ClinicalTrials.gov registry record · Phase 2
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05114460 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 2 participants.
The verdict
NCT05114460, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana \[Delta-9-tetrahydracannabinol (THC)\] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.
Interventions
- DRUG Naloxone
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05114460
The ClinicalTrials.gov registry entry for NCT05114460 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naloxone is the first listed.
NCT05114460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05114460 about?
NCT05114460 is a clinical study titled "Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal". The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana \[Delta-9-tetrahydracannabinol (THC)\] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.
What is the current status of trial NCT05114460?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-11-01. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT05114460?
The interventions under investigation include: Naloxone (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT05114460?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.